Can-Fite BioPharma rallies on rheumatoid arthritis data

|About: Can-Fite Biopharma Ltd (CANF)|By:, SA News Editor

Can-Fite BioPharma (CANF) jumps 18% in premarket action.

The company says a Phase 2b study of the A3AR agonist CF101 in RA "met all primary efficacy endpoints."

ACR20 response rates: CF101, 49%; placebo, 25%; p=0.035.

Responses were cumulative, indicating "a consistent anti-inflammatory effect."

The company calls the treatment's safety profile "excellent." (PR)